Casey House releases Big Fucking Deal, a short film examining the compounding effects of stigma for people living with HIV




Casey House releases Big Fucking Deal, a short film examining the compounding effects of stigma for people living with HIV

Study reveals only 44% of Canadians are confident that people living with HIV receive stigma-free health care when they need it – a gap the film recognizes through storytelling

TORONTO, Feb. 17, 2026 (GLOBE NEWSWIRE) — Casey House – a hospital unlike any other providing care for people living with and at risk of HIV – today announces the release of Big Fucking Deal, directed by Academy Award–nominated filmmaker Hubert Davis, as part of the hospital’s ongoing Smash Stigma campaign.

Thanks to decades of scientific innovation, HIV is medically manageable for many people. But the ability to access and sustain consistent HIV care is not equally shared, especially when barriers compound and reinforce one another. A study commissioned by Casey House found that more than half of Canadians (54%) don’t feel they understand what it means to live with HIV today – a gap that leaves stigma unchallenged and barriers unseen. Big Fucking Deal responds by demonstrating how stigma intensifies and outcomes diverge when an HIV diagnosis intersects with challenges such as housing insecurity, substance use dependency, mental health challenges, and discrimination tied to identity.

“We’ve made extraordinary progress in HIV treatment, but equity has not kept pace,” said Joanne Simons, CEO, Casey House. “This film, the sixth edition of our longstanding Smash Stigma initiative, is a call to see the full humanity of people living with HIV. It asks Canadians to replace assumption with understanding and empathy, especially when other challenges are present in people’s lives.”

For people navigating multiple barriers at once, the difference between treatment being available and treatment being truly accessible and sustainable can be enormous. It can mean trying to stay connected to care without stable housing, managing mental illness amid trauma or poverty, or facing discrimination that makes seeking support feel unsafe. The film centres these realities not to sensationalize them, but to make visible what stigma often obscures: the human cost of being misunderstood, unsupported, or judged.

“We approached this as a human story first, not a diagnosis,” said Hubert Davis, founder of Folktale films and director of the film. “It’s about what people are carrying, and how that load is magnified for those living with HIV but also confronting difficult realities of housing, mental illness and substance use dependency. We wanted to honour that reality without over-simplifying it. If Big Fucking Deal does one thing, I hope it helps people see stigma differently and see the person first.”

This tension shows up in what Canadians think it takes to live with HIV today. Medication is widely understood, with 82% of Canadians saying consistent access to medication is typically required to stay healthy. However, fewer recognize the role of stigma-free health care (63%) and stable housing (48%) in making consistent care possible. Trust in care is also fragile: only 44% of Canadians say they are confident that people living with HIV in Canada receive stigma-free health care when they need it.

“The science is clear: HIV treatment works. But there are still gaps in understanding, and too little confidence that people will receive stigma-free care when they need it,” said Yasser Ismail, Chief Strategy & Knowledge Officer, Casey House. “That’s exactly the gap Casey House exists to close, by meeting people where they are and ensuring care is delivered with dignity and without judgement.”

Watch and learn more
To watch the film, learn more about the campaign and Casey House’s work to deliver compassionate, stigma-free HIV care, visit SmashStigma.ca.

High-res images and campaign assets can be found here.

To book an interview with any of our following spokespeople or for more information about Big Fucking Deal please contact:

Sheri Clish
sheri.clish@narrativexpr.com

Spokespeople available for interviews include:

• Joanne Simons, CEO of Casey House
• Hubert Davis, film Director
• Norrad Bouzide, Person with lived experience accessing and providing care

About Casey House:
Casey House is unlike any other hospital. They are a specialty hospital in Toronto providing ground-breaking care to people living with and at risk of HIV. Together with clients, staff, peers and volunteers, they strive to create an inclusive environment where everyone feels safe. Casey House offers a growing mix of inpatient, and outpatient services that meet clients where they are in their individual journeys of health and wellness and actively dismantle barriers to care and safe living. As a hospital that strives to create an inclusive environment where everyone feels safe, they’re also tackling the deeply ingrained stigma associated with HIV. With bold ideas and brave partners, they make the humanity of each client the heart of everything they do.

Survey Methodology:
These findings are from a survey conducted by Casey House from January 16 to 20, 2026, among a representative sample of 1,511 online Canadians who are members of the Angus Reid Forum. The survey was conducted in English and French. For comparison purposes only, a probability sample of this size would carry a margin of error of +/-2.5 percentage points, 19 times out of 20.

Oculis Appoints Katie Kazem as Chief Legal Officer




Oculis Appoints Katie Kazem as Chief Legal Officer

• Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companies
• Chief Legal Officer (CLO) appointment enhances leadership capabilities to advance three highly differentiated late-stage assets toward near-term clinical and regulatory milestones

ZUG, Switzerland, February 17, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced the appointment of Katie Kazem as Chief Legal Officer, leading Oculis’ legal, compliance and corporate governance functions. Ms. Kazem brings extensive expertise in corporate and securities law, with a distinguished track record advising public and private life sciences companies on complex transactions and regulatory matters.

Riad Sherif, M.D., Chief Executive Officer of Oculis, stated “Katie joins Oculis at an exciting moment, with Privosegtor advancing into the PIONEER program with registrational trials for a novel neuroprotective platform and just ahead of the much-anticipated DIAMOND Phase 3 topline results for OCS-01 eye drops in DME, expected in Q2. This significant momentum reinforces our commitment to delivering transformational therapies. I look forward to working alongside Katie as we continue to make rapid progress across our highly differentiated pipeline and prepare for important late-stage clinical, regulatory, and commercial milestones.”

Katie Kazem, Chief Legal Officer of Oculis, said “I am honored to be joining Oculis at such an important stage of the company’s journey to become a global leader in neuro-ophthalmology and ophthalmology. Over the past few years, I have had the privilege of serving as external legal counsel to Oculis since its listing on NASDAQ in March 2023, which allowed me to work closely with its exceptional executive team and board of directors, witness the company’s remarkable progress and unwavering business integrity, and gain deeper insight into its highly promising pipeline. I look forward to continuing this collaboration as we advance the company’s late-stage assets toward future clinical milestones and commercialization.”

Ms. Kazem brings to Oculis over 15 years of experience representing life sciences companies on US initial public offerings (IPOs), capital raising, M&A and strategic transactions, SEC compliance, and corporate governance. She joins Oculis from Cooley LLP, a leading international law firm, where she was a capital markets partner. At Cooley, she represented dozens of publicly traded life sciences and technology companies in their IPOs, acquisitions, follow-on offerings, and strategic licensing transactions. She has particular expertise in advising dual-listed biotechnology companies across Europe. Her experience spans both company-side and underwriter-side representations across the life sciences and technology sectors. Ms. Kazem earned her JD, magna cum laude, from George Mason University School of Law, a Master’s degree in Public Policy from George Mason University School of Public Policy, and a BA in Government from the College of William & Mary.

-ENDS-

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a breakthrough neuroprotective candidate in the PIONEER program which consists of studies intended to support registration plans for treatment in optic neuropathies like optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in Phase 2, which is being developed with a genotype-based approach to drive precision medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, the initiation, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy, including planned interactions with the FDA; Oculis’ future development plans; the timing or likelihood of regulatory filings and approvals; statements about market opportunity, and the Company’s expected financial position and cash runway, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Oculis Appoints Katie Kazem as Chief Legal Officer




Oculis Appoints Katie Kazem as Chief Legal Officer

ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) —

• Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companies
• Chief Legal Officer (CLO) appointment enhances leadership capabilities to advance three highly differentiated late-stage assets toward near-term clinical and regulatory milestones

Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced the appointment of Katie Kazem as Chief Legal Officer, leading Oculis’ legal, compliance and corporate governance functions. Ms. Kazem brings extensive expertise in corporate and securities law, with a distinguished track record advising public and private life sciences companies on complex transactions and regulatory matters.

Riad Sherif, M.D., Chief Executive Officer of Oculis, stated “Katie joins Oculis at an exciting moment, with Privosegtor advancing into the PIONEER program with registrational trials for a novel neuroprotective platform and just ahead of the much‑anticipated DIAMOND Phase 3 topline results for OCS‑01 eye drops in DME, expected in Q2. This significant momentum reinforces our commitment to delivering transformational therapies. I look forward to working alongside Katie as we continue to make rapid progress across our highly differentiated pipeline and prepare for important late‑stage clinical, regulatory, and commercial milestones.”

Katie Kazem, Chief Legal Officer of Oculis, said “I am honoured to be joining Oculis at such an important stage of the company’s journey to become a global leader in neuro-ophthalmology and ophthalmology. Over the past few years, I have had the privilege of serving as external legal counsel to Oculis since its listing on NASDAQ in March 2023, which allowed me to work closely with its exceptional executive team and board of directors, witness the company’s remarkable progress and unwavering business integrity, and gain deeper insight into its highly promising pipeline. I look forward to continuing this collaboration as we advance the company’s late‑stage assets toward future clinical milestones and commercialization.”

Ms. Kazem brings to Oculis over 15 years of experience representing life sciences companies on US initial public offerings (IPOs), capital raising, M&A and strategic transactions, SEC compliance, and corporate governance. She joins Oculis from Cooley LLP, a leading international law firm, where she was a capital markets partner. At Cooley, she represented dozens of publicly traded life sciences and technology companies in their IPOs, acquisitions, follow-on offerings, and strategic licensing transactions. She has particular expertise in advising dual-listed biotechnology companies across Europe. Her experience spans both company-side and underwriter-side representations across the life sciences and technology sectors. Ms. Kazem earned her JD, magna cum laude, from George Mason University School of Law, a Master’s degree in Public Policy from George Mason University School of Public Policy, and a BA in Government from the College of William & Mary.

-ENDS-

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a breakthrough neuroprotective candidate in the PIONEER program which consists of studies intended to support registration plans for treatment in optic neuropathies like optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in Phase 2, which is being developed with a genotype-based approach to drive precision medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, the initiation, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy, including planned interactions with the FDA; Oculis’ future development plans; the timing or likelihood of regulatory filings and approvals; statements about market opportunity, and the Company’s expected financial position and cash runway, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference




FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference

• Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD

HEIDELBERG, Germany, Feb. 17, 2026 (GLOBE NEWSWIRE) — FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators aimed at delivering rapid and sustained relief for patients with treatment-resistant depression (TRD), today announces its recognition as one of twelve leading companies selected to present at the prestigious Bio-Neuroscience Conference, the premier global gathering of neuroscience innovation leaders, investors, and pharmaceutical executives. This event will take place from February 24–26, 2026, in Amsterdam, The Netherlands, showcasing organizations that demonstrate excellence and leadership in neuroscience research and therapeutic innovation.

NMDAR is the most compelling clinically validated target for TRD, which affects over 30% of patients with major depressive disorders (MDD) who do not respond to at least two different antidepressants. Through its innovative, neurobiology‑driven approach, FundaMental Pharma aims to redefine the treatment paradigm for TRD and meaningfully improve outcomes for patients with severe unmet medical needs.

The presentation by Dr. Dirk Beher, Chief Executive Officer of FundaMental Pharma, will highlight the scientific foundation for lead candidate FMP374, the distinctive approach to modulating NMDAR, and the compelling preclinical data that support its advancement toward IND-enabling studies.

“Our selection at this prestigious conference highlights our scientific breakthrough and validates the significant commercial and therapeutic potential of our approach to treatment-resistant depression,” commented Dr. Dirk Beher, Chief Executive Officer of FundaMental Pharma. “We are committed to addressing critical unmet needs for patients with TRD. FMP374 leverages a clinically validated target and introduces a proprietary dual-acting mechanism, aiming to deliver compelling efficacy alongside superior pharmacological margins, over unwanted side effects. This innovation represents a transformative opportunity to set a new benchmark in TRD treatment and unlock substantial value for patients, clinicians, and our stakeholders.”

FundaMental Pharma’s lead candidate, FMP374, is an orally bioavailable, dual-acting NMDAR modulator that uniquely combines the disruption of the NMDAR/TRPM4 complex with NMDAR antagonism. This novel mechanism aims to enhance antidepressant efficacy while reducing the exaggerated NMDAR pharmacology associated with current standards of care (SOC). Current SOC requires supervised, in-clinic administration due to risks of dissociation and hallucination. FMP374 is designed to address these challenges while preserving the rapid onset advantages of NMDAR-targeted treatments.

A variety of studies of FMP374 have demonstrated rapid and sustained antidepressant effects in gold-standard depression models at low nanomolar unbound CNS drug concentrations, with exceptional ≥10–20x margins, over unwanted NMDAR-related side effects. Importantly, FMP374 shows no evidence of dissociation-like behaviors, hallucination-associated proxies, ataxia, or hyperactivity at efficacious doses in representative models, supporting its potential as an oral, at-home therapy for patients with TRD. Its novel dual-acting mechanism positions FMP374 as a transformative solution for those unresponsive to existing antidepressants. Backed by robust preclinical data, FMP374 is ready for IND-enabling studies.

Details of the presentation are as follows:

Location: Hotel Jakarta, Amsterdam, The Netherlands
Presentation Title: Novel Dual-Acting NMDA Receptor Modulators for Treatment-Resistant Depression
Date & Time: Wednesday, 25 February 2026 – 16:45 CET
Presenter: Dr. Dirk Beher, Chief Executive Officer, FundaMental Pharma

Bio-Neuroscience is an initiative of Broadreach Global, co-organized with Host Partners Amsterdam Neuroscience.

For more information, please contact:

Optimum Strategic Communications
Zoe Bolt, Elena Bates, Nellie Stephens
+44 (0) 203 882 9621
fundamentalpharma@optimumcomms.com

About FundaMental Pharma
FundaMental Pharma GmbH is a preclinical, biopharmaceutical company committed to advancing mental health by addressing treatment-resistant depression (TRD). Established as a spin-off from Heidelberg University, FundaMental Pharma is headquartered in Heidelberg, Germany. Its research builds on the pioneering work of Professor Hilmar Bading and Dr. Jing Yan, published in Science (Yan et al., 2020), leading to the development of proprietary dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators.

These dual-acting molecules uniquely disrupt the complex formed between NMDAR and the transient receptor potential cation channel subfamily M member 4 (TRPM4), while simultaneously acting as potent NMDAR antagonists.

FMP374 has shown robust antidepressant‑like efficacy at low nanomolar concentrations, without evidence of dissociation‑associated behaviors, ataxia, or hyperactivity at efficacious doses in preclinical proof-of-concept studies, supporting its potential as an at‑home therapy. The molecule is orally bioavailable and ready for IND‑enabling studies. Through its innovative, neurobiology‑driven approach, FundaMental Pharma aims to redefine the treatment paradigm for TRD and meaningfully improve outcomes for patients with severe unmet medical needs. For further information, please visit https://fundamentalpharma.com/.

About Bio-Neuroscience
Bio-Neuroscience is the leading international event where pioneers, leaders and decision-makers in neuroscience drug development gather for 2.5 days of uninterrupted, high-level, high-impact and interactive discussions, networking and business development. Taking place February 24-26, 2026 at Hotel Jakarta in Amsterdam, the summit is limited to just 200 senior stakeholders, including CEOs of high-potential neuroscience drug development companies both private and publicly listed, Managing Partners, Partners and Directors of leading Corporate Venture and Venture Capital funds actively investing in the sector, Global Heads of Healthcare Investment Banking, CEOs and C-Level executives from top neuroscience specialty pharma, and Heads of Therapeutic Area and Business Development and Licensing from top 20 big pharma active in the space, as well as key opinion leaders and regulatory officials. Bio-Neuroscience is an initiative of Broadreach Global, co-organized with Amsterdam Neuroscience. For more information and registration, visit www.bio-neuroscience.com.

Inventiva reports preliminary 2025¹ fiscal year financial results




Inventiva reports preliminary 2025¹ fiscal year financial results

• Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits² as of December 31, 2025
• Revenues of €4.5 million in 2025
• Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million³)
• Cash runway expected until the middle of the first quarter of 2027⁴

Daix (France), New York City (New York, United States), February 17, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its certain preliminary unaudited financial results for the full year ending December 31, 2025, including cash, cash equivalents, and revenues.

Cash and cash equivalents

As of December 31, 2025, the Company’s cash and cash equivalents amounted to €99.3 million and its short-term deposits² to €131.6 million, compared to cash and cash equivalents of €96.6 million as of December 31, 2024.

Net cash used in operating activities amounted to (€104.6) million in 2025, compared to (€85.9) million in 2024, representing an increase of 22%. R&D expenses, mainly related to the development of lanifibranor in MASH, amounted to €86.9 million in 2025, down 4% from €90.9 million in 2024. The increase in net cash used in operating activities is mainly related to the net cash impact of the strategic pipeline prioritization plan for the Company’s activities implemented in the first half of 2025, lower revenues under the licensing agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“CTTQ”), and an increase in general and administrative expenses.

Net cash used in investing activities amounted to (€133.2) million in 2025, mainly related to the subscription of new short-term deposits² during the period, compared with €8.7 million generated in 2024.

Net cash generated by financing activities amounted to €241.1 million in 2025, compared to €145.6 million in 2024. This positive cash flow is mainly due to the receipt of (i) gross proceeds of €115.6 million (net proceeds of €108.0 million) from the second tranche⁵ in May 2025 of the structured financing announced by the Company in October 2024 (the “Structured Financing”), and (ii) gross proceeds of $172.5 million (net proceeds of €139.3 million) from the public offering in the United States in November 2025.

In 2025, the Company recorded a negative exchange rate effect on cash and cash equivalents of (€0.5) million, compared to a positive effect of €1.2 million in 2024, due to changes in the EUR/USD exchange rate.

Given its current cost structure and projected expenses, the Company estimates that its cash, cash equivalents, and short-term deposits, should enable it to finance its operations until the middle of the first quarter of 2027. Assuming the potential exercise in full of the Tranche 3 warrants issued in the Structured Financing for proceeds of up to €116.0 million, the Company estimates that such potential additional proceeds would enable it to finance its activities until the middle of the third quarter of 2027⁶.

Revenues

The Company’s revenues in 2025 amounted to €4.5 million, compared to €9.2 million generated in 2024.

Revenues recorded by the Company in 2025 consist mainly of the $10 million gross proceeds (net proceeds of €8.6 million) milestone payment invoiced to CTTQ and the $5 million (€4.3 million) credit notes recognized under the license agreement with CTTQ following the closing of the second tranche of the Structured Financing in May 2025. The milestone payment from CTTQ was received in July 2025.

***                                               

Next financial results publication

• Financial audited results for the full fiscal year 2025: March 30, 2026 (after U.S. market close).

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). http://www.inventivapharma.com   

Contacts

 Avertissement

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release are forward-looking statements. These statements include, but are not limited to, preliminary unaudited financial information, forecasts and estimates regarding Inventiva’s cash resources and expenses, the potential exercise by investors of warrants and pre-funded warrants, including warrants and pre-funded warrants issued in connection with the Structured Financing, forecasts and estimates with respect to Inventiva’s NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH, including design, duration, timing, costs, and funding, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of lanifibranor, potential regulatory submissions, approvals and commercialization, Inventiva’s pipeline and development plans, and Inventiva’s future activities, expectations, plans, growth and prospects. Some of these statements, forecasts, and estimates may be identified by the use of words such as, without limitation, “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “estimate,” “may,” “will,” “could,” “should,” “designed,” “hope,” “target,” “potential,” “opportunity,” “possible,” “aim,” and “continue” and other similar expressions. These statements are not historical facts, but rather statements of future expectations and other forward-looking statements based on management’s beliefs. These statements reflect the opinions and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend on factors beyond Inventiva’s control. There can be no guarantee, with respect to product candidates, that clinical trial results will be available on schedule, that future clinical trials will be initiated as planned, that product candidates will receive the necessary regulatory approvals, or that the milestones planned by Inventiva or its partners will be achieved on schedule, or even at all. Future results may differ materially from the anticipated future results, performance, or achievements expressed or implied by these statements, forecasts, and estimates due to a number of factors, including  the completion of financial closing procedures, final audit adjustments and other developments that may arise that could cause the preliminary financial results for 2025 to differ from the financial results that will be reflected in Inventiva’s audited consolidated financial statements for the fiscal year ended December 31, 2025,  the fact that interim data or data from any interim analysis of ongoing clinical trials do not predict the future results of clinical trials, the fact that the DMC’s recommendation does not prejudge any eventual marketing authorization, that Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on recruitment or the final impact on the results or timing of the NATiV3 trial or related regulatory issues, Inventiva is a clinical-stage company with no approved products and no historical revenue, Inventiva has incurred significant losses since its inception, Inventiva has never generated revenue from product sales, Inventiva will need additional capital to fund its operations, without which Inventiva may be required to significantly reduce its activities, delay or discontinue one or more of its research or development programs, expand its activities or capitalize on its business opportunities, and may not be able to continue as a going concern. Inventiva’s ability to obtain financing and complete potential transactions on a timely basis, as well as whether, when, and to what extent dilutive instruments may be exercised and by which holders, Inventiva’s future success depends on the successful clinical development, regulatory approvals, and subsequent commercialization of lanifibranor, preclinical studies or previous clinical trials are not necessarily predictive of future results, and the results of Inventiva’s and its partners’ clinical trials may not support Inventiva’s and its partners’ claims regarding product candidates, Inventiva’s expectations regarding its clinical trials may prove to be incorrect, and regulatory authorities may require additional stops and/or modifications to Inventiva’s clinical trials. Inventiva’s expectations regarding the clinical development plan for lanifibranor for the treatment of MASH may not be realized and may not support the approval of a New Drug Application, Inventiva’s ability to identify other products or product candidates with significant commercial potential, Inventiva’s expectations regarding its strategic reorganization plan and the resulting reduction in headcount, including the potential benefits, expenses, and consequences thereof, Inventiva’s ability to implement its commercialization, marketing, and manufacturing capabilities and strategy, Inventiva’s ability to successfully cooperate with its existing partners or enter into new partnerships, and to fulfill its obligations under any agreements entered into in connection with such partnerships, the benefits of its current and future partnerships on the clinical development, regulatory approvals, and, if applicable, commercialization of its product candidates, as well as the achievement of milestones and timelines anticipated in connection with such partnerships, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of the applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, the recruitment and retention of patients in clinical trials is a costly and time-consuming process that could be made more difficult or impossible by multiple factors beyond the control of Inventiva and its partners, Inventiva’s product candidates may cause adverse reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces significant competition, and Inventiva’s activities, preclinical studies, and clinical development programs, as well as timelines, Inventiva’s financial condition and results of operations could be materially and adversely affected by changes in laws and regulations, adverse conditions in its industry, geopolitical events, such as the conflict between Russia and Ukraine and the resulting sanctions, the conflict in the Middle East and the related risk of a wider conflict, epidemics, and macroeconomic conditions, including changes in international trade policies, global inflation, fluctuations in financial and credit markets, customs duties and other trade barriers, political unrest and natural disasters, uncertain financial markets, and disruptions in banking systems. In light of these risks and uncertainties, no representation is made as to the accuracy or completeness of these forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts, and estimates are only valid as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements.

Please refer to the Universal Registration Document for the fiscal year ended December 31, 2024, filed with the Autorité des Marchés Financiers on April 15, 2025, the semi-annual financial report as of June 30, 2025, published on September 29, 2025, and the Annual Report on Form 20-F  for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2025 for other risks and uncertainties affecting Inventiva, including those described under the heading “Risk Factors,” and in future filings with the SEC. Other risks and uncertainties that Inventiva is not currently aware of may also affect its forward-looking statements and may cause actual results and timing of events to differ materially from those anticipated. All information contained in this press release is current as of the date of this release. Except as required by law, Inventiva has no intention or obligation to update or revise the forward-looking statements mentioned above. Therefore, Inventiva accepts no responsibility for the consequences arising from the use of any of the above statements.

¹ Preliminary non audited financial information.
² Short-term deposits were classified as “other current assets” in the consolidated statement of financial position in accordance with IFRS and were considered by the Company to be liquid and readily available.
³ Based on the exchange rate of €1.00 = $1.1576 as published by the European Central Bank on November 12, 2025. See press release of November 17, 2025. 
⁴ This estimate is based on the Company’s current business plan and excludes potential milestone payments to be paid or received by the Company, any potential additional proceeds from the exercise of Tranche 3 share purchase warrants issued as part of the Structured Financing, as well as any additional expenses related to other product candidates or resulting from the licensing or acquisition of additional product candidates or technologies, or any related developments that the Company may pursue. The Company may have based this estimate on incorrect assumptions and may end up using its resources more quickly than anticipated.
⁵ Press release 5 May 2025
⁶ These estimates are based on the Company’s current business plan and exclude any milestone payments that may be made by or to the Company, as well as any additional expenses related to other product candidates or resulting from a potential license agreement or acquisition of additional product candidates or technologies, or any associated development that the Company may pursue. The Company may have based these estimates on assumptions that are incorrect, and the Company may end up using its resources more quickly than anticipated. There is no guarantee that the warrants in Tranche 3 will be exercised, if at all.

Attachment

• Inventiva – PR – Preliminary FY 2025 – EN – 02 17 2026

FIRST PATIENT DOSED IN CITRYLL’S IMAGING STUDY EVALUATING DISTRIBUTION AND TARGET ENGAGEMENT OF CIT-013




FIRST PATIENT DOSED IN CITRYLL’S IMAGING STUDY EVALUATING DISTRIBUTION AND TARGET ENGAGEMENT OF CIT-013

• PET-based imaging study designed to assess the biodistribution of CIT-013 and associate disease activity with CIT-013 target disposition in participants with rheumatoid arthritis and hidradenitis suppurativa
• Findings will be additive to outcomes of ongoing Phase IIa studies in both indications, which launched in 2025

Oss, Netherlands – 17 February 2026 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Extracellular Traps (ETs), today announces that the first patient has been successfully dosed in its imaging study, ‘Cityview’, evaluating the distribution of radiolabeled CIT-013 in participants with rheumatoid arthritis (RA) and hidradenitis suppurativa (HS).

Cityview has been designed to assess the biodistribution of CIT-013 in the body using PET-CT imaging in participants with RA and HS. The study will evaluate the antibody’s target engagement and disposition as well as the link between disease activity and CIT-013 distribution – the presence at specific sites of inflammation. Cityview follows a preclinical study in mice which showed congruence between PET-CT based imaging of radiolabelled-CIT-013 and clinically inflamed joints and stands as a critical step in validating CIT-013’s mechanisms of action.

Cityview is a Phase IIa, open-label, single-center study planned to enroll 12 participants in two sequential groups starting with participants with active RA, followed by participants with RA in remission and participants with active HS. Following a single dose of radiolabeled CIT-013, participants will undergo PET-CT imaging at intervals over a week follow-up period. The study will also explore the effect on immune system response, pharmacokinetics, and safety, with optional lymph node biopsies offering deeper insight into CIT-013’s mechanism of action in affected tissue.

Maarten Kraan, Chief Medical Officer of Citryll, said, “This is a crucial study that will deepen our understanding on CIT-013’s biodistribution and target engagement, while informing the ongoing Phase IIa and future Phase IIb studies in rheumatoid arthritis and hidradenitis suppurativa. Beyond applying these insights in our own clinical development, we look forward to sharing findings with the wider inflammatory disease community as milestones are reached. We remain convinced that an ET-targeting approach has the potential to be transformative for these underserved patient groups”

This imaging study comes alongside two ongoing Phase IIa trials: Citydream in RA, and Citylights in HS, assessing the efficacy, safety, and tolerability of CIT-013.

-ENDS-

About CIT-013

CIT-013 is Citryll’s first-in-class monoclonal antibody targeting Extracellular Traps (ETs), a key driver of inflammation in RA and other immune-mediated diseases, which has yet to be addressed therapeutically. It has a unique dual mechanism of action, which enhances the clearance of existing ETs and inhibits the formation of new ETs. CIT-013 is highly selective for its epitope, minimizing off-target effects and representing a potentially transformative therapeutic strategy, going beyond individual pathway management and symptom treatment.

About Citryll

Citryll is pioneering a transformative approach to treating inflammatory diseases by targeting Extracellular Traps (ETs), a fundamental component of the inflammatory process that has yet to be addressed therapeutically.

Citryll is developing the first ET-targeting therapy and potentially creating a new class of therapeutics with broad applications across immune-mediated inflammatory diseases.

Our lead asset, CIT-013, is a first-in-class monoclonal antibody with a unique dual mechanism of action: it enhances the clearance of existing ETs and inhibits the formation of new ETs.

By addressing this key driver of inflammation, CIT-013 has the potential to offer a differentiated and comprehensive treatment option for conditions such as rheumatoid arthritis and hidradenitis suppurativa, where current therapies often fall short of providing adequate disease control.

Contacts

Citryll
Sjoerd van Gorp, COO / CFO
Email: info@citryll.com

Citryll Media Contacts
ICR Healthcare
Amber Fennell, Stephanie Cuthbert, Lucy Featherstone
Email: citryll@icrinc.com

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026




Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

Management will participate in three upcoming investor healthcare conferences

SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the fourth quarter and full year 2025.

A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.

Upcoming Investor Conferences
Sam Raha, President and CEO, and Ben Wheeler, Chief Financial Officer, will participate in the following investor healthcare conferences:

• The TD Cowen 46th Annual Health Care Conference in a fireside chat at 3:10 pm ET on Tuesday, March 3, 2026.
• The Leerink Partners Global Healthcare Conference in a fireside chat at 1:40 pm ET on Tuesday, March 10, 2026.
• The Barclays 28^th Annual Global Healthcare conference in 1-on-1 meetings on Wednesday, March 11, 2026.

Live and archived webcasts of presentations at TD Cowen and Leerink Partners can be viewed at investor.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Kate Schraml
(385) 318-3718 
PR@myriad.com  

Matterhorn Fit Debuts in Fort Lauderdale with Olympian and Florida Panthers alum Steven Kampfer at the Helm




Matterhorn Fit Debuts in Fort Lauderdale with Olympian and Florida Panthers alum Steven Kampfer at the Helm

FORT LAUDERDALE, Fla., Feb. 16, 2026 (GLOBE NEWSWIRE) — Matterhorn Fit, a cutting-edge fitness and rehabilitation facility, has officially opened its doors in Fort Lauderdale. Co-founded by Olympian and Florida Panthers alum Steven Kampfer and his wife, Tara Kampfer, a former University of Miami athlete, the new franchise brings Matterhorn Fit’s innovative neurological rehabilitation and performance training techniques to South Florida.

“We’re thrilled to bring Matterhorn Fit to Fort Lauderdale,” said Steven Kampfer. “Our goal is to provide a revolutionary way for people to improve mobility, reduce pain, and enhance their overall quality of life.”

Matterhorn Fit’s proprietary process boasts a remarkable success rate significantly reducing chronic pain within two weeks of treatment. Matterhorn Fit helps athletes and individuals overcome physical barriers and achieve peak performance. The new Fort Lauderdale facility aims to provide the same world-class protocols used by professional athletes and Olympians to the local community – from weekend warriors and active seniors to student-athletes.

Matterhorn Fit Fort Lauderdale inspires HOPE within our clients with their “Matterhorn Method”

• Diagnose: The process begins with a proprietary diagnostic scan to identify exactly where the brain-to-muscle signal is inhibited.
• Reconnect: Specialized protocols are used to “unlock” these neurological compensations and re-establish the neural pathways.
• Reinforce: Once the connection is restored, specific movement patterns are used to ensure the nervous system “remembers” how to fire those muscles correctly.
• Strengthen: Finally, the individual moves into elite-level performance training to build a stable, pain-free foundation.

Since opening, Matterhorn Fit Fort Lauderdale has already attracted a roster of elite athletes, including Olympic sailors and professional hockey players. The facility’s personalized programs are designed for individuals of all fitness levels, making its benefits accessible to the wider community.

Matterhorn Fit Fort Lauderdale will be offering complimentary initial evaluations for all new customers until the end of March 2026.

For more information, visit at www.matterhornfit.com/fort-lauderdale or follow Matterhorn Fit Fort Lauderdale on social media @matterhornfit_fortlauderdale

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/44721c4f-c6ea-47b4-ad39-d9c594b3edfb

CONTACT: Tara Kampfer
(305) 934-5506
tkampfer@matterhornfit.com
Matterhorn Fit Fort Lauderdale